Morgan Stanley
Duplicate source posts collapse into one event. Only direct subject-company stories are included in this public hub.
Morgan Stanley upgraded HOOD to Overweight with a $150 PT (from $124). Analyst sees product breadth improving customer economics and extending growth duration beyond account growth or retail trading cycles.
macro · Impact 60Morgan Stanley lifted its Q4 Brent forecast to $100/bbl from $75 and WTI to $96 from $76. The bank also issued Q1 and Q2 2027 forecasts. A separate WSJ survey shows bank consensus for 2026 and 2027 averages.
analyst action · Impact 30Morgan Stanley downgraded the European tobacco sector to Equal Weight from Overweight. The move signals a more cautious view on the industry.
analyst action · Impact 10Morgan Stanley cut its rating on the European paper and packaging sector to Underweight from Equal Weight. No rationale was provided.
sector · Impact 20Morgan Stanley downgraded the European telecoms sector to Equal Weight from Overweight. The move signals a more neutral view on the sector after a period of overweight positioning. No specific stocks or rationale were disclosed in the initial report.
analyst action · Impact 30Morgan Stanley lifts NVIDIA target price to $300 from $288.
analyst action · Impact 30Morgan Stanley says CXMT's higher growth reflects China AI server demand and localization-driven capacity expansion. The bank expects continued expansion even if DRAM prices soften. Bull case includes US customers and a 3D DRAM breakthrough by 2028. CXMT may use VCT technology to reach Gen5 without EUV.
analyst action · Impact 10Morgan Stanley upgraded Dynatrace to Overweight from Equalweight and raised its price target to $65 from $58, citing a durable acceleration in ARR growth driven by a large renewal cohort and platform breadth.
macro · Impact 40Morgan Stanley's Wilson: oil spike is biggest risk to US stocks, recommends energy hedge.
analyst action · Impact 10Morgan Stanley initiated coverage of ArcelorMittal (MT) with an Overweight rating and a price target of $82 per share. The initiation signals a positive outlook on the steelmaker's prospects.
analyst action · Impact 30Morgan Stanley initiated coverage of Rio Tinto with an Underweight rating and a $90 price target. The bearish call suggests limited upside potential for the mining giant.
analyst action · Impact 40Morgan Stanley upgrades Merck to Overweight, lifts price target to $179.
analyst action · Impact 10Morgan Stanley maintains $335 base target on Amazon. Bull case of $500 by end-2027 assumes AWS accelerates toward $1T annual revenue. Amazon raised 2026 AI spending forecast to $220B.
analyst action · Impact 60Morgan Stanley's Brian Nowak maintains a $335 base-case price target on Amazon but lifts the bull case to $500, driven by a view that AWS can grow to $1 trillion in annual revenue over 8–10 years. Nowak estimates Amazon will add 6–8 GW of compute capacity in 2026/2027 and sees AI margins tracking ahead of the core AWS business at a similar stage. Compute capacity is the key gating factor.
corporate action · Impact 70Morgan Stanley reiterated its $300 price target on SpaceX with a $600 bull case after the company completed its $60 billion acquisition of AI coding platform Cursor. The bank sees Cursor ARR reaching $8B by year-end and $33B by 2030. Analyst Adam Jonas views the approaching lock-up expiry as a buying opportunity.
macro · Impact 10Morgan Stanley expects the Fed to stay on hold through year-end as inflation continues to cool. Tariff pass-through is largely complete, energy pressures are contained, and shelter inflation is moderating. The bank forecasts 50 bps of cuts in 2027, split between March and June.
macro · Impact 60Morgan Stanley forecasts that AI compute demand will outpace supply for several years. The outlook supports continued capital spending on AI hardware and data centers.
analyst action · Impact 30Morgan Stanley analyst Erik Woodring upgraded HPE to Overweight with a $69 target. He sees HPE as the best play on the enterprise infrastructure cycle, with networking becoming a higher-margin growth driver and improving financial flexibility. Execution is the key risk.
earnings · Impact 20Morgan Stanley's weekly tracker shows total US prescription growth decelerated to 1.5% YoY for the week ended July 31. Among individual drugs, GILD's Yeztugo stood out: Morgan Stanley sees $1.049B in US sales vs $988M consensus, citing strong persistence and payer coverage. Script counts for BMY, VRTX, and JNJ drugs were stable to slightly higher.
Explore the exact intelligence modules available on every supported company page.
